Published in Ann Neurol on September 01, 2007
Evidence-based guideline: pharmacologic treatment of chorea in Huntington disease: report of the guideline development subcommittee of the American Academy of Neurology. Neurology (2012) 2.34
NMDA receptors in clinical neurology: excitatory times ahead. Lancet Neurol (2008) 2.13
Calcium signaling and neurodegenerative diseases. Trends Mol Med (2009) 2.03
Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: the NNIPPS study. Brain (2008) 1.72
Symptomatic treatment of Huntington disease. Neurotherapeutics (2008) 1.08
Tetrabenazine: the first approved drug for the treatment of chorea in US patients with Huntington disease. Neuropsychiatr Dis Treat (2010) 1.06
Role of inositol 1,4,5-trisphosphate receptors in pathogenesis of Huntington's disease and spinocerebellar ataxias. Neurochem Res (2011) 1.04
Dopamine and glutamate in Huntington's disease: A balancing act. CNS Neurosci Ther (2010) 1.03
Mouse models of Huntington disease: variations on a theme. Dis Model Mech (2009) 1.02
Neuroprotection for Huntington's disease: ready, set, slow. Neurotherapeutics (2008) 0.92
Corticostriatal circuit dysfunction in Huntington's disease: intersection of glutamate, dopamine and calcium. Future Neurol (2010) 0.89
Riluzole in psychiatry: a systematic review of the literature. Expert Opin Drug Metab Toxicol (2008) 0.89
Neuroprotective effects of psychotropic drugs in Huntington's disease. Int J Mol Sci (2013) 0.88
The Current Status of Neural Grafting in the Treatment of Huntington's Disease. A Review. Front Integr Neurosci (2011) 0.87
Therapeutic potential of metabotropic glutamate receptor modulators. Curr Neuropharmacol (2012) 0.85
Target- and mechanism-based therapeutics for neurodegenerative diseases: strength in numbers. J Med Chem (2013) 0.84
Calcium signaling and neurodegeneration. Acta Naturae (2010) 0.83
Riluzole protects Huntington disease patients from brain glucose hypometabolism and grey matter volume loss and increases production of neurotrophins. Eur J Nucl Med Mol Imaging (2009) 0.83
Treatment of Huntington's disease. Neurotherapeutics (2014) 0.82
Therapeutic prospects for spinocerebellar ataxia type 2 and 3. Drugs Future (2009) 0.82
Psychosis, Treatment Emergent Extrapyramidal Events, and Subsequent Onset of Huntington's Disease: A Case Report and Review of the Literature. Clin Psychopharmacol Neurosci (2016) 0.81
Perceived stress in prodromal Huntington disease. Psychol Health (2011) 0.80
Pharmacological treatment of chorea in Huntington's disease-good clinical practice versus evidence-based guideline. Mov Disord (2013) 0.79
Motor neuron disease: focusing the mind on ALS: updated practice parameters. Nat Rev Neurol (2010) 0.78
Current Pharmacological Approaches to Reduce Chorea in Huntington's Disease. Drugs (2016) 0.78
Recent advances in the management of choreas. Ther Adv Neurol Disord (2013) 0.77
How to Capitalize on the Retest Effect in Future Trials on Huntington's Disease. PLoS One (2015) 0.75
Inositol 1,4,5-tripshosphate receptor, calcium signaling, and polyglutamine expansion disorders. Curr Top Membr (2010) 0.75
Protective Effect of Antioxidants on Neuronal Dysfunction and Plasticity in Huntington's Disease. Oxid Med Cell Longev (2017) 0.75
The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement (2011) 21.80
Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord (2008) 9.52
Clinical diagnostic criteria for dementia associated with Parkinson's disease. Mov Disord (2007) 6.92
Genome-wide association study identifies 19p13.3 (UNC13A) and 9p21.2 as susceptibility loci for sporadic amyotrophic lateral sclerosis. Nat Genet (2009) 4.38
Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Process, format, and clinimetric testing plan. Mov Disord (2007) 3.86
Delusions and hallucinations are associated with worse outcome in Alzheimer disease. Arch Neurol (2005) 3.10
Apathy and the functional anatomy of the prefrontal cortex-basal ganglia circuits. Cereb Cortex (2005) 2.80
Direct evidence for a parietal-frontal pathway subserving spatial awareness in humans. Science (2005) 2.68
Dementia with Lewy bodies. Lancet Neurol (2004) 2.66
Long-term use of standardised Ginkgo biloba extract for the prevention of Alzheimer's disease (GuidAge): a randomised placebo-controlled trial. Lancet Neurol (2012) 2.65
Cognitive dysfunction in psychiatric disorders: characteristics, causes and the quest for improved therapy. Nat Rev Drug Discov (2012) 2.44
TARDBP mutations in motoneuron disease with frontotemporal lobar degeneration. Ann Neurol (2009) 2.30
Prediction of conversion from mild cognitive impairment to Alzheimer's disease dementia based upon biomarkers and neuropsychological test performance. Neurobiol Aging (2010) 2.27
X-linked bulbospinal neuronopathy: Kennedy disease. Arch Neurol (2002) 2.21
Are amygdalar volume alterations in children with Tourette syndrome due to ADHD comorbidity? Dev Med Child Neurol (2008) 2.11
Support vector machine-based classification of Alzheimer's disease from whole-brain anatomical MRI. Neuroradiology (2008) 2.09
Cognitive control and brain resources in major depression: an fMRI study using the n-back task. Neuroimage (2005) 2.02
Energy metabolism in amyotrophic lateral sclerosis. Lancet Neurol (2010) 2.00
Testing objective measures of motor impairment in early Parkinson's disease: Feasibility study of an at-home testing device. Mov Disord (2009) 2.00
Designing drug trials for Alzheimer's disease: what we have learned from the release of the phase III antibody trials: a report from the EU/US/CTAD Task Force. Alzheimers Dement (2013) 1.98
Multidimensional classification of hippocampal shape features discriminates Alzheimer's disease and mild cognitive impairment from normal aging. Neuroimage (2009) 1.95
Functions of the left superior frontal gyrus in humans: a lesion study. Brain (2006) 1.89
Phenotype variability in progranulin mutation carriers: a clinical, neuropsychological, imaging and genetic study. Brain (2008) 1.84
Two German kindreds with familial amyotrophic lateral sclerosis due to TARDBP mutations. Arch Neurol (2008) 1.78
Shining a light on posterior cortical atrophy. Alzheimers Dement (2012) 1.77
Mutations in potassium channel kcnd3 cause spinocerebellar ataxia type 19. Ann Neurol (2012) 1.70
Progranulin null mutations in both sporadic and familial frontotemporal dementia. Hum Mutat (2007) 1.69
Four familial ALS pedigrees discordant for two SOD1 mutations: are all SOD1 mutations pathogenic? J Neurol Neurosurg Psychiatry (2010) 1.68
Discrimination between Alzheimer disease, mild cognitive impairment, and normal aging by using automated segmentation of the hippocampus. Radiology (2008) 1.64
Time to redefine PD? Introductory statement of the MDS Task Force on the definition of Parkinson's disease. Mov Disord (2014) 1.63
Anatomically constrained region deformation for the automated segmentation of the hippocampus and the amygdala: Method and validation on controls and patients with Alzheimer's disease. Neuroimage (2006) 1.60
Steps to standardization and validation of hippocampal volumetry as a biomarker in clinical trials and diagnostic criterion for Alzheimer's disease. Alzheimers Dement (2011) 1.59
Body mass index is associated with biological CSF markers of core brain pathology of Alzheimer's disease. Neurobiol Aging (2011) 1.57
Global brain atrophy and corticospinal tract alterations in ALS, as investigated by voxel-based morphometry of 3-D MRI. Amyotroph Lateral Scler Other Motor Neuron Disord (2005) 1.55
Parkinson's disease dementia can be easily detected in routine clinical practice. Mov Disord (2010) 1.53
Lack of association between serum uric acid levels and outcome in acute ischemic stroke. J Neurol Sci (2012) 1.47
Images in cardiovascular medicine. Cardiomyopathy in a Duchenne muscular dystrophy carrier and her diseased son: similar pattern revealed by cardiovascular MRI. Circulation (2010) 1.47
Risk factors for alveolar echinococcosis in humans. Emerg Infect Dis (2004) 1.46
Angiogenin variants in Parkinson disease and amyotrophic lateral sclerosis. Ann Neurol (2011) 1.45
Distinct brain perfusion pattern associated with CSF biomarkers profile in primary progressive aphasia. J Neurol Neurosurg Psychiatry (2012) 1.44
Distinct patterns of antiamyloid-β antibodies in typical and atypical Alzheimer disease. Arch Neurol (2012) 1.44
Do CTG expansions at the SCA8 locus cause ataxia? Ann Neurol (2003) 1.43
Heterozygous R1101K mutation of the DCTN1 gene in a family with ALS and FTD. Ann Neurol (2005) 1.42
Can we still dream when the mind is blank? Sleep and dream mentations in auto-activation deficit. Brain (2013) 1.42
Severity of depressive symptoms and quality of life in patients with amyotrophic lateral sclerosis. Neurorehabil Neural Repair (2005) 1.40
Targeted next-generation sequencing of a 12.5 Mb homozygous region reveals ANO10 mutations in patients with autosomal-recessive cerebellar ataxia. Am J Hum Genet (2010) 1.40
Visuospatial deficits in posterior cortical atrophy: structural and functional correlates. J Neurol Neurosurg Psychiatry (2012) 1.39
Disruptive behavior as a predictor in Alzheimer disease. Arch Neurol (2007) 1.39
Pathogenesis of cerebral amyloid angiopathy. Brain Res Brain Res Rev (2003) 1.35
Mitochondrial impairment in patients and asymptomatic mutation carriers of Huntington's disease. Mov Disord (2005) 1.33
The chemokine CXCL13 is a prognostic marker in clinically isolated syndrome (CIS). PLoS One (2010) 1.32
Disconnecting force from money: effects of basal ganglia damage on incentive motivation. Brain (2008) 1.31
NR2A and NR2B receptor gene variations modify age at onset in Huntington disease. Neurogenetics (2004) 1.31
Neural correlates of cognitive impairment in posterior cortical atrophy. Brain (2011) 1.30
Cognitive impairment in patients with multiple system atrophy and progressive supranuclear palsy. Brain (2010) 1.30
Amyotrophic lateral sclerosis--a model of corticofugal axonal spread. Nat Rev Neurol (2013) 1.29
Prodynorphin mutations cause the neurodegenerative disorder spinocerebellar ataxia type 23. Am J Hum Genet (2010) 1.27
Executive dysfunctions as potential markers of familial vulnerability to bipolar disorder and schizophrenia. Psychiatry Res (2004) 1.27
The chemokine CXCL13 in acute neuroborreliosis. J Neurol Neurosurg Psychiatry (2009) 1.26
IgG antibodies against measles, rubella, and varicella zoster virus predict conversion to multiple sclerosis in clinically isolated syndrome. PLoS One (2009) 1.25
Similar amyloid-β burden in posterior cortical atrophy and Alzheimer's disease. Brain (2011) 1.25
Whole brain-based analysis of regional white matter tract alterations in rare motor neuron diseases by diffusion tensor imaging. Hum Brain Mapp (2010) 1.23
Parkinson's disease dementia: definitions, guidelines, and research perspectives in diagnosis. Ann Neurol (2008) 1.21
Annual rate and predictors of conversion to dementia in subjects presenting mild cognitive impairment criteria defined according to a population-based study. Dement Geriatr Cogn Disord (2004) 1.20
Apathy in patients with mild cognitive impairment and the risk of developing dementia of Alzheimer's disease: a one-year follow-up study. Clin Neurol Neurosurg (2006) 1.18
Glutamate levels in cerebrospinal fluid in amyotrophic lateral sclerosis: a reappraisal using a new HPLC method with coulometric detection in a large cohort of patients. J Neurol Sci (2002) 1.18
ARSACS in the Dutch population: a frequent cause of early-onset cerebellar ataxia. Neurogenetics (2008) 1.17
C9ORF72 repeat expansions in the frontotemporal dementias spectrum of diseases: a flow-chart for genetic testing. J Alzheimers Dis (2013) 1.16
Disease severity and progression in progressive supranuclear palsy and multiple system atrophy: validation of the NNIPPS--Parkinson Plus Scale. PLoS One (2011) 1.15
Depressive symptoms in Alzheimer's disease: natural course and temporal relation to function and cognitive status. J Am Geriatr Soc (2005) 1.15
A review of compliance to treatment in Alzheimer's disease: potential benefits of a transdermal patch. Curr Med Res Opin (2007) 1.15
Alternative trial design in amyotrophic lateral sclerosis saves time and patients. Amyotroph Lateral Scler (2007) 1.15
NR2A and NR2B receptor gene variations modify age at onset in Huntington disease in a sex-specific manner. Hum Genet (2007) 1.13
The modulation of Amyotrophic Lateral Sclerosis risk by ataxin-2 intermediate polyglutamine expansions is a specific effect. Neurobiol Dis (2011) 1.12
Assessment of simple movements reflects impairment in Huntington's disease. Mov Disord (2006) 1.11
Reliability and validity of the International Cooperative Ataxia Rating Scale: a study in 156 spinocerebellar ataxia patients. Mov Disord (2006) 1.10
Neuroectodermally converted human mesenchymal stromal cells provide cytoprotective effects on neural stem cells and inhibit their glial differentiation. Cytotherapy (2010) 1.10
Frontotemporal dementia: pathology of gait? Mov Disord (2010) 1.10
Assessment of complex movements reflects dysfunction in Huntington's disease. J Neurol (2003) 1.10
Accelerated aging phenotype in mice with conditional deficiency for mitochondrial superoxide dismutase in the connective tissue. Aging Cell (2010) 1.09
A randomized, double blind, placebo-controlled trial of pioglitazone in combination with riluzole in amyotrophic lateral sclerosis. PLoS One (2012) 1.09
A point mutation in the dynein heavy chain gene leads to striatal atrophy and compromises neurite outgrowth of striatal neurons. Hum Mol Genet (2010) 1.09
Get aroused and be stronger: emotional facilitation of physical effort in the human brain. J Neurosci (2009) 1.08
Histopathological analysis of skeletal muscle in patients with Parkinson's disease and 'dropped head'/'bent spine' syndrome. Parkinsonism Relat Disord (2009) 1.08
Demographic, neurological and behavioural characteristics and brain perfusion SPECT in frontal variant of frontotemporal dementia. Brain (2006) 1.08
Late-onset motoneuron disease caused by a functionally modified AMPA receptor subunit. Proc Natl Acad Sci U S A (2005) 1.06
NF-κB is required for Smac mimetic-mediated sensitization of glioblastoma cells for γ-irradiation-induced apoptosis. Mol Cancer Ther (2011) 1.06
Frontal assessment battery and differential diagnosis of frontotemporal dementia and Alzheimer disease. Arch Neurol (2004) 1.06
Linking neuron and skin: matrix metalloproteinases in amyotrophic lateral sclerosis (ALS). J Neurol Sci (2009) 1.05
Mice with a mutation in the dynein heavy chain 1 gene display sensory neuropathy but lack motor neuron disease. Exp Neurol (2008) 1.05
Phosphoinositide 3-kinases upregulate system xc(-) via eukaryotic initiation factor 2α and activating transcription factor 4 - A pathway active in glioblastomas and epilepsy. Antioxid Redox Signal (2014) 1.05
Cerebrospinal fluid biomarkers in the differential diagnosis of Alzheimer's disease from other cortical dementias. J Neurol Neurosurg Psychiatry (2010) 1.04
Brain hemispheres selectively track the expected value of contralateral options. J Neurosci (2009) 1.04
Grey-matter abnormalities in boys with Tourette syndrome: magnetic resonance imaging study using optimised voxel-based morphometry. Br J Psychiatry (2006) 1.04
Deciphering logopenic primary progressive aphasia: a clinical, imaging and biomarker investigation. Brain (2013) 1.02
FUS mutations in frontotemporal lobar degeneration with amyotrophic lateral sclerosis. J Alzheimers Dis (2010) 1.02
The functional architecture of the left posterior and lateral prefrontal cortex in humans. Cereb Cortex (2008) 1.02
Laryngospasm: an underdiagnosed symptom of X-linked spinobulbar muscular atrophy. Neurology (2005) 1.01